Xencor is trading at $32.50, up 8.37% in pre-market on October 28, extending its rally after updated Phase 1 results for XmAb819 showed a 45.5% confirmed response rate at the selected dose. - The pre-market price compares with the October 27 close of $29.99. - The company reported cash runway into 2029. - Analysts raised price targets after the data, adding to the positive reaction to the update.